# Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Study · id `cardio:ct-nct05359068` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05359068](<https://clinicaltrials.gov/study/NCT05359068>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05359068

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 957 participants.

## Technical summary

Registry record NCT05359068. Randomized; double masking; primary purpose treatment. Start 2021-06-10 (actual); primary completion 2023-12-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 957 participants (enrolled count; ClinicalTrials.gov record NCT05359068, source copy `cardio:ctgov-nct05359068-2024-05-07`, retrieved 2026-10-26)
- Started: 2021-06-10 (actual) (ClinicalTrials.gov record NCT05359068, source copy `cardio:ctgov-nct05359068-2024-05-07`, retrieved 2026-10-26)
- Primary completion: 2023-12-26 (actual) (ClinicalTrials.gov record NCT05359068, source copy `cardio:ctgov-nct05359068-2024-05-07`, retrieved 2026-10-26)
- Completion: 2023-12-26 (actual) (ClinicalTrials.gov record NCT05359068, source copy `cardio:ctgov-nct05359068-2024-05-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05359068, source copy `cardio:ctgov-nct05359068-2024-05-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05359068-2024-05-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): SPH3127 tablet
- Intervention (Drug): SPH3127 tablet
- Intervention (Drug): SPH3127 tablet
- Intervention (Drug): Valsartan
- Intervention (Drug): SPH3127 tablet
- Intervention (Drug): Valsartan
- Lead sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry lists this organization as the lead sponsor: Shanghai Pharmaceuticals Holding Co., Ltd (`cardio:org-shanghai-pharmaceuticals-holding-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial (`cardio:pubmed-42165988`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 291e3c74cd6528de31c97f01156edbf4d646b5586ee05e6ba8568ec73848121f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
